

Serial No. 09/502,176

Title: Deglycosylated Kringle 1-3 Region Fragments of Plasminogen and Methods of Use  
Amendment and Response to Office Action

Filed: February 10, 2000

Page 2

RECEIVED  
CENTRAL FAX CENTER  
JUL 07 2006

### AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A composition comprising a pharmaceutically acceptable carrier and a protein consisting of a deglycosylated kringle 1-3 region fragment of a plasminogen protein, wherein the deglycosylated kringle 1-3 region fragment lacks one or more two carbohydrate moieties found in ~~moieties linked to~~ naturally glycosylated forms of the fragment, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity, and wherein the deglycosylated kringle 1-3 region fragment and a glycosylated form of the fragment are at a ratio of 100:0.

2. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment lacks a bisialylated-biantennary glycan.

3. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment lacks an N-linked carbohydrate moiety.

4. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment lacks a carbohydrate chain at an amino acid position corresponding to an N-glycosylation site of human plasminogen.

5. (Cancelled)

6. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment begins at approximately amino acid 87 of human plasminogen.

6. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment amino acid sequence is shown in SEQ ID NO:2.

Serial No. 09/502,176

Title: Deglycosylated Kringle 1-3 Region Fragments of Plasminogen and Methods of Use  
Amendment and Response to Office Action

Filed: February 10, 2000

Page 3

~~7~~ 8. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment is produced recombinantly.

~~8~~ 9. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment has an amino acid substitution at amino acid position corresponding to the N-glycosylation site of human plasminogen.

10-14. (Cancelled)

~~9~~ 15. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity *in vitro*.

~~10~~ 16. (Previously Presented) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity *in vivo*.

17-26 (Cancelled)

~~11~~ 27. (Previously Presented) A deglycosylated kringle 1-3 region fragment of a plasminogen protein, wherein the deglycosylated kringle 1-3 region fragment amino acid sequence is shown in SEQ ID NO:2.

28. (Cancelled)

~~20~~ 29. (Previously Presented) The composition of claim ~~40~~<sup>19</sup>, wherein the amount of the naturally glycosylated kringle 1-3 region fragment present in the composition is smaller than the amount of the deglycosylated kringle 1-3 region fragment present in the composition.

30-34. (Cancelled)

Serial No. 09/502,176

Title: *Deglycosylated Kringle 1-3 Region Fragments of Plasminogen and Methods of Use*

Amendment and Response to Office Action

Filed: February 10, 2000

Page 4

<sup>16</sup> 35. (Previously Presented) The composition of claim <sup>15</sup> 39, wherein the deglycosylated kringle 1-3 region fragment is produced recombinantly.

36. (Cancelled)

<sup>17</sup> 37. (Previously Presented) The composition of claim <sup>15</sup> 39, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity *in vitro*.

<sup>18</sup> 38. (Previously Presented) The composition of claim <sup>15</sup> 39, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity *in vivo*.

<sup>15</sup> 39. (Previously Presented) A composition comprising a pharmaceutically acceptable carrier and a protein consisting of a deglycosylated kringle 1-3 region fragment of a plasminogen protein wherein the deglycosylated kringle 1-3 region fragment lacks one or more carbohydrate moieties linked to naturally glycosylated forms of the fragment, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity, and wherein the deglycosylated kringle 1-3 region fragment amino acid sequence is shown in SEQ ID NO:2.

<sup>19</sup> 40. (Previously Presented) The composition of claim <sup>15</sup> 39, further comprising a protein consisting of a naturally glycosylated kringle 1-3 region fragment of a plasminogen protein.

<sup>12</sup> 41. (Currently Amended) The deglycosylated kringle 1-3 region fragment composition of claim <sup>11</sup> 27, wherein the deglycosylated kringle 1-3 region fragment is produced recombinantly.

Serial No. 09/502,176

Title: *Deglycosylated Kringle 1-3 Region Fragments of Plasminogen and Methods of Use*  
Amendment and Response to Office Action

Filed: February 10, 2000

Page 5

<sup>13</sup> 42. (Currently Amended) The deglycosylated kringle 1-3 region fragment  
~~composition~~ of claim <sup>11</sup>27, wherein the deglycosylated kringle 1-3 region fragment has  
antiangiogenic activity *in vitro*.

<sup>14</sup> 43. (Currently Amended) The deglycosylated kringle 1-3 region fragment  
~~composition~~ of claim <sup>11</sup>27, wherein the deglycosylated kringle 1-3 region fragment has  
antiangiogenic activity *in vivo*.